Champions Oncology (CSBR) Capital Expenditures (2010 - 2026)
Champions Oncology (CSBR) posted quarterly Capital Expenditures of $239000.0 for Q2 2026, up 712.82% year-over-year from $29403.8 in Q2 2025, and up 545.95% quarter-over-quarter from $37000.0 in Q1 2026.
Champions Oncology (CSBR) Capital Expenditures (2010 - 2026) Analysis & Trends
Champions Oncology's Capital Expenditures history runs 17 years deep, the most recent figure standing at $239000.0 for Q2 2026.
- In Q2 2026, Capital Expenditures rose 712.82% year-over-year to $239000.0; the TTM figure through Apr 2026 stood at $564000.0 (up 44.99% YoY), while the FY2026 annual figure was $564000.0, up 44.99% from the prior year.
- Capital Expenditures for Q2 2026 stood at $239000.0, up from $37000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $760000.0 in Q2 2023, with the low at -$39000.0 in Q2 2025.
- The 5-year median for Capital Expenditures is $286000.0 (2025), against an average of $327764.7.
- The sharpest annual moves came in 2025 and 2026: Capital Expenditures slumped 1200.0% in 2025, then soared 712.82% in 2026.
- Champions Oncology's Capital Expenditures stood at $604000.0 in 2022, then plunged by 86.92% to $79000.0 in 2023, then increased by 18.99% to $94000.0 in 2024, then slumped by 97.87% to $2000.0 in 2025, then jumped by 11850.0% to $239000.0 in 2026.
- Business Quant data shows CSBR's Capital Expenditures at $239000.0 in Q2 2026, $37000.0 in Q1 2026, and $2000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn | 239,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 239,000.00 |
| Apr 30, 2026 | 239,000.00 |
| Jan 31, 2026 | 37,000.00 |
| Jan 31, 2026 | 37,000.00 |
| Oct 31, 2025 | 2,000.00 |
| Oct 31, 2025 | 2,000.00 |
| Jul 31, 2025 | 286,000.00 |
| Jul 31, 2025 | 286,000.00 |
| Apr 30, 2025 | -39,000.00 |
| Apr 30, 2025 | -39,000.00 |
| Jan 31, 2025 | 334,000.00 |
| Jan 31, 2025 | 334,000.00 |
| Oct 31, 2024 | 94,000.00 |
| Oct 31, 2024 | 94,000.00 |
| Apr 30, 2024 | -3,000.00 |
| Apr 30, 2024 | -3,000.00 |
| Jan 31, 2024 | 92,000.00 |
| Jan 31, 2024 | 92,000.00 |
| Oct 31, 2023 | 79,000.00 |
| Oct 31, 2023 | 79,000.00 |